| abstract |
FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to psychiatry, and can be used for diagnosing asthenic syndrome in schizophrenic patients. That is ensured by measuring the enzymatic activity of leukocyte elastase and the functional activity of the alpha-1 proteinase inhibitor in the patient's blood serum of schizophrenia. If the ratio of the enzymatic activity of leukocyte elastase to the value of the functional activity of the alpha-1 proteinase inhibitor (leukocyte-inhibitor index) is within range of 3.10–4.34, the asthenia is diagnosed in the patient, and if this ratio is in range 4.85–6.31 – absence of asthenia. n EFFECT: invention provides objective diagnostics of schizoasthenia on the basis of proteolytic-inhibitor system of blood serum. n 1 cl, 1 tbl, 2 ex |